TTP Survival Rates Jump to 95% Thanks to Century of Medical Breakthroughs

This landmark review commemorates 100 years since thrombotic thrombocytopenic purpura (TTP) was first described, showcasing one of medicine's most dramatic success stories in transforming a nearly universally fatal disease into one with over 95% survival rates.

The European Society of Intensive Care Medicine's educational initiative traces TTP's evolution from Eli Moschcowitz's 1924 description to today's sophisticated treatments. The breakthrough came with discovering ADAMTS13 deficiency as TTP's central mechanism, caused either by autoantibodies in immune TTP or genetic mutations in congenital TTP.

This pathophysiological understanding enabled targeted therapies including therapeutic plasma exchange, caplacizumab (an anti-von Willebrand factor nanobody), and recombinant ADAMTS13. These treatments specifically address the underlying ADAMTS13 deficiency rather than just managing symptoms.

The review emphasizes improved diagnostic capabilities and differential diagnosis methods, crucial for early intervention. It highlights collaborative efforts between clinicians, researchers, and industry that drove these advances over the past century.

While representing remarkable progress, the authors note continued challenges in early recognition and optimal treatment sequencing. The initiative aims to further improve outcomes by sharing best practices and raising awareness among healthcare providers who may encounter this rare but critical condition.